News and Trends 22 Dec 2022 First CAR-T technology trial for patients with T-cell leukemia subtype authorized The Spanish Agency of Medicines and Medical Products (AEMPS) has approved the CARxALL clinical trial led by the company OneChain Immunotherapeutics (OCI). It will be the world’s first trial with CAR-T technology for patients with a subtype of T-cell leukemia. The CARxALL trial will evaluate, for the first time, the CAR-T CD1a (OC-1) therapy. This […] December 22, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 20 Dec 2022 Ebvallo approval ushers in off-the-shelf T-cell immunotherapies Patient-derived CAR-T immunotherapies have dominated the cancer immunotherapy space over the last decade. The EU approval of Atara Biotherapeutics’ Ebvallo marks the first immunotherapy based on T cells sourced from healthy donors. Since the approvals of Kymriah and Yescarta in 2017, CAR-T immunotherapies have changed the way we treat rare forms of blood cancer. In […] December 20, 2022 - 6 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 21 Nov 2022 Legend Biotech small cell lung cancer drug gets FDA ok for clinical development Legend Biotech Corporation has announced that the U.S. Food and Drug Administration (FDA) has cleared Legend Biotech’s investigational new drug (IND) application to proceed with the clinical development of LB2102, an investigational, autologous chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of adult patients with extensive stage small cell lung cancer (SCLC). LB2102 is […] November 21, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 10 Nov 2022 SOTIO reveal potential treatment for adults with solid tumors at SITC meeting SOTIO Biotech has presented preclinical results of its BOXR T cell therapy platform and revealed it indicates a strong clinical path for its first transgene-expressing CAR-T cell as a potential treatment for solid tumors in adults with cancer. The results were presented at the Society for Immunotherapy of Cancer’s (SITC) 37th annual meeting taking place […] November 10, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 8 Nov 2022 Collaboration to develop CAR-T cell therapy for cutaneous T-cell lymphoma The Peter MacCallum Cancer Centre (Peter Mac) and Cartherics Pty Ltd (Cartherics) have entered into a collaborative development program agreement (CDPA) to develop Cartherics’ proprietary autologous CAR-T cell therapy (CTH-001) for the treatment of cutaneous T-cell lymphoma (CTCL). “Patients with advanced stages of cutaneous T-cell lymphomas often have few treatment options left when their disease […] November 8, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Oct 2022 Spanish research institution to use Elicera Therapeutics’ iTANK platform Elicera Therapeutics AB has entered a material transfer agreement with the Josep Carreras Leukaemia Research Institute (JCLRI) in Spain for use of the iTANK platform in arming CAR T-cells for the treatment of Ewing Sarcoma. Sweden’s Elicera is a clinical stage cell and gene therapy company developing next generation immuno-oncological treatments based on enhanced oncolytic […] October 20, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 11 Oct 2022 The biggest private biotech investments in September 2022 The companies Acelyrin, InnovaFeed and Arsenal Biosciences bagged the biggest biotech investments in September 2022, with insect protein and cell therapies attracting big funding rounds. Autumn is in full swing in the Northern Hemisphere. After a breather in August 2022, September saw the return of big fundraising activity for biotech companies. We’ve gathered the biggest […] October 11, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 7 Oct 2022 Mission Bio launches first commercial high-throughput cell therapy assay for measuring vector copy number Mission Bio has announced the availability of the Tapestri VCN Assay, the first high-throughput commercial single-cell assay to simultaneously quantify vector copy number (VCN) and transduction at the level of individual cells. For the first time, developers of cell therapies like CAR-T cells will be able to apply multi-omic analysis to assess the cell-to-cell variability […] October 7, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 27 Sep 2022 Bioheng Biotech has positive CAR-T cell therapy results published in academic journal Positive results from a phase 1 clinical study of RD13-01, an anti-CD7 universal CAR-T therapy product, have been published in reputable academic journal, Cell Research. China-based Bioheng Biotech Co. Ltd, a clinical-stage biotechnology company focused on developing novel cellular immunotherapy made the announcement today (September 27). The results published with the title of ‘CD7-targeted allogeneic CAR-T […] September 27, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
Interview 27 Sep 2022 Natural killer cells: a thriving frontier in allogeneic cell therapy Kai Pinkernell, chief medical officer at Glycostem, discusses how natural killer (NK) cell therapies could usher in off-the-shelf cancer immunotherapies. Since their first approvals in 2017, chimeric antigen receptor (CAR)-T cell immunotherapies have showcased the potential of immuno-oncology in providing long-lasting treatments for cancer. This impact was felt in not just the CAR-T cell therapy […] September 27, 2022 - 6 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Startup Scout 22 Sep 2022 Cartography Biosciences unearths cancer immunotherapy targets Despite its meteoric growth in the last twenty years, cancer immunotherapy research is hamstrung by a lack of viable drug targets. Cartography Biosciences is using a single-cell sequencing approach to meet this demand. Immuno-oncology as a field barely existed 20 years ago, but has rapidly grown into a thriving field of biotechnology research. This has […] September 22, 2022 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Startup Scout 15 Sep 2022 Adva Biotechnology is using artificial intelligence to manufacture cell therapies The manufacturing of cell therapies is highly complex, often depending on skilled manual labor. The Israeli startup Adva Biotechnology aims to use automation, optical sensing and artificial intelligence to remove the manual component from the process. Cancer cell therapies such as CAR-T immunotherapies have demonstrated enormous potential for treating forms of blood cancer. Currently available […] September 15, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email